{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:03:05Z","timestamp":1787698985785,"version":"build-2784847793"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100025154","name":"University of Sadat City","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100025154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic nephropathy (DN) is a significant complication of diabetes, leading to chronic kidney failure and end-stage renal disease. While traditional treatments exist, innovative strategies are being investigated to enhance DN management. This study examines a novel nanosized formulation of carvedilol (CVL), a drug recognized for its \u03b2-blocker and \u03b1-1-adrenoreceptor antagonist properties. We developed a self-nanoemulsifying drug delivery system (SNEDS) to assess its potential in improving DN outcomes. DN was induced in rats using streptozotocin (STZ), and the animals received oral administration of either CVL or CVL-SNEDS for 6\u00a0weeks. We measured body weight, blood glucose levels, creatinine, blood urea nitrogen (BUN), albumin-creatinine ratio (ACR), kidney injury molecule-1 (KIM-1), oxidative stress, and inflammation. Kidney tissues were also examined for damage and fibrosis markers, particularly transforming growth factor beta-1 (TGF-\u03b21). Diabetic rats exhibited weight loss, hyperglycemia, elevated creatinine, BUN, ACR, KIM-1, increased oxidative stress, and inflammation, along with notable renal damage and higher TGF-\u03b21 expression. Treatment with CVL-SNEDS significantly improved these parameters, reducing blood glucose levels by 51%, creatinine by 39%, BUN by 67%, and ACR by 78%, while also alleviating inflammation and oxidative stress and protecting against kidney damage and fibrosis. These findings suggest that CVL-SNEDS may represent a promising therapeutic approach for slowing DN progression by enhancing glycemic control and mitigating fibrosis, inflammation, and oxidative stress.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Schematic diagram showing the mechanism of SNEDS-loaded CVL as potential treatment strategies for type-1 diabetes mellitus and renal fibrosis. This mechanism includes the reduction of TNF-\u03b1 &amp; IL-1\u03b2 expression, antioxidant activity, and activation of the KIM1\/TGF-\u03b21\/TNF-\u03b1 signaling cascade.<\/jats:p>","DOI":"10.1007\/s00210-025-04356-9","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:11:59Z","timestamp":1750227119000},"page":"17695-17709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Carvedilol-loaded self-nanoemulsifying drug delivery system target diabetic nephropathy: preclinical evidence of antioxidant and antifibrotic effects"],"prefix":"10.1007","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-9957","authenticated-orcid":false,"given":"Hanan","family":"Elimam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-0939","authenticated-orcid":false,"given":"Nora A. A.","family":"Alhamshry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"El-Say","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5737-1166","authenticated-orcid":false,"given":"Ahmed M. A.","family":"Akabawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"4356_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40659-024-00527-9","volume":"57","author":"MG Aboismaiel","year":"2024","unstructured":"Aboismaiel MG, Amin MN, Eissa LA (2024) Renoprotective effect of a novel combination of 6-gingerol and metformin in high-fat diet\/streptozotocin-induced diabetic nephropathy in rats via targeting miRNA-146a, miRNA-223, TLR4\/TRAF6\/NLRP3 inflammasome pathway and HIF-1\u03b1. Biol Res 57:47","journal-title":"Biol Res"},{"key":"4356_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/03639045.2017.1405977","volume":"44","author":"TA Ahmed","year":"2018","unstructured":"Ahmed TA, El-Say KM, Hosny KM, Aljaeid BM (2018) Development of optimized self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical pharmacokinetic behavior. Drug Dev Ind Pharm 44:652\u2013661","journal-title":"Drug Dev Ind Pharm"},{"key":"4356_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.21608\/ejmr.2024.254949.1507","volume":"5","author":"MH Ahmed","year":"2024","unstructured":"Ahmed MH, Abdullah NH, Mostafa SO, Abd Elaal AT, Matar HS (2024) Relation between kidney injury molecule 1 (KIM 1) and diabetic nephropathy. Egypt J Med Res 5:80\u201391","journal-title":"Egypt J Med Res"},{"key":"4356_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3389\/fphar.2020.01119","volume":"11","author":"AL Alaofi","year":"2020","unstructured":"Alaofi AL (2020) Sinapic acid ameliorates the progression of streptozotocin (STZ)-induced diabetic nephropathy in rats via NRF2\/HO-1 mediated pathways. Front Pharmacol 11:1119","journal-title":"Front Pharmacol"},{"key":"4356_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jddst.2018.04.015","volume":"46","author":"HM Aldawsari","year":"2018","unstructured":"Aldawsari HM, Elfaky MA, Fahmy UA, Aljaeid BM, Alshareef OA, Khalid M (2018) Development of a fluvastatin-loaded self-nanoemulsifying system to maximize therapeutic efficacy in human colorectal carcinoma cells. J Drug Deliv Sci Technol 46:7\u201313","journal-title":"J Drug Deliv Sci Technol"},{"key":"4356_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/13813455.2021.1890129","volume":"129","author":"AS Alshehri","year":"2023","unstructured":"Alshehri AS (2023) Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2\/Ho-1\/antioxidants axis. Arch Physiol Biochem 129:984\u2013997","journal-title":"Arch Physiol Biochem"},{"key":"4356_CR7","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.jnutbio.2020.108515","volume":"87","author":"JZ ALTamimi","year":"2021","unstructured":"ALTamimi JZ, AlFaris NA, Al-Farga AM, Alshammari GM, BinMowyna MN, Yahya MA (2021) Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKC\u03b2\/p66Shc axis and activation of FOXO-3a. J Nutr Biochem 87:108515","journal-title":"J Nutr Biochem"},{"key":"4356_CR8","doi-asserted-by":"publisher","first-page":"106813","DOI":"10.1016\/j.intimp.2020.106813","volume":"87","author":"S Alzahrani","year":"2020","unstructured":"Alzahrani S, Zaitone SA, Said E, El-Sherbiny M, Ajwah S, Alsharif SY, Elsherbiny NM (2020) Protective effect of isoliquiritigenin on experimental diabetic nephropathy in rats: Impact on Sirt-1\/NF\u03baB balance and NLRP3 expression. Int Immunopharmacol 87:106813","journal-title":"Int Immunopharmacol"},{"key":"4356_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00755-7","volume":"19","author":"PR Amarachinta","year":"2021","unstructured":"Amarachinta PR, Sharma G, Samed N, Chettupalli AK, Alle M, Kim J-C (2021) Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect. J Nanobiotechnol 19:1\u201315","journal-title":"J Nanobiotechnol"},{"key":"4356_CR10","doi-asserted-by":"publisher","first-page":"155394","DOI":"10.1016\/j.cyto.2020.155394","volume":"138","author":"K Amirshahrokhi","year":"2021","unstructured":"Amirshahrokhi K, Zohouri A (2021) Carvedilol prevents pancreatic \u03b2-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-\u03baB, COX-2, iNOS and oxidative stress. Cytokine 138:155394","journal-title":"Cytokine"},{"key":"4356_CR11","first-page":"383","volume":"22","author":"G Aydin","year":"2003","unstructured":"Aydin G, Ozcelik N, Cicek E, Soyoz M (2003) Histopathologic changes in liver and renal tissues induced by ochratoxin A and melatonin in rats. Hum Exp Toxicol 22:383\u2013391","journal-title":"Hum Exp Toxicol"},{"key":"4356_CR12","volume-title":"Histochemical techniques","author":"JD Bancroft","year":"2013","unstructured":"Bancroft JD (2013) Histochemical techniques. Butterworth-Heinemann"},{"key":"4356_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"key":"4356_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","volume":"6","author":"Y Chen","year":"2020","unstructured":"Chen Y, Lee K, Ni Z, He JC (2020) Diabetic kidney disease: challenges, advances, and opportunities. Kidney Dis 6:215\u2013225","journal-title":"Kidney Dis"},{"key":"4356_CR15","doi-asserted-by":"publisher","first-page":"15476","DOI":"10.1021\/acsomega.0c01618","volume":"5","author":"H Elimam","year":"2020","unstructured":"Elimam H, El-Say KM, Cybulsky AV, Khalil H (2020) Regulation of autophagy progress via lysosomal depletion by fluvastatin nanoparticle treatment in breast cancer cells. ACS Omega 5:15476\u201315486","journal-title":"ACS Omega"},{"key":"4356_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jcb.30238","volume":"123","author":"H Elimam","year":"2022","unstructured":"Elimam H, Hussein J, Abdel-Latif Y, Abdel-Aziz AK, El-Say KM (2022) Preclinical activity of fluvastatin-loaded self-nanoemulsifying delivery system against breast cancer models: Emphasis on apoptosis. J Cell Biochem 123:947\u2013963","journal-title":"J Cell Biochem"},{"key":"4356_CR17","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1002\/jbt.70057","volume":"38","author":"H Elimam","year":"2024","unstructured":"Elimam H, Gauvin J, Huynh DN, Menard L, Al-Hawat ML, Harb D, Lubell WD, Carpentier AC, Ong H, Marleau S (2024) Targeting CD36 with EP 80317 reduces remote inflammatory response to hind limb ischemia-reperfusion in mice. J Biochem Mol Toxicol 38:e70057","journal-title":"J Biochem Mol Toxicol"},{"key":"4356_CR18","doi-asserted-by":"crossref","unstructured":"Elimam H, El-Say KM, Ahmed TA, Marleau S, El-Khayat Z, El-Banna M, Hussein J (2025) Nanoformulation of valsartan-loaded tablet attenuates L-NAME-induced hypertension: role of Nrf2\/PPARgamma\/AT1 signaling pathway. Naunyn Schmiedebergs Arch Pharmacol","DOI":"10.1007\/s00210-025-03993-4"},{"key":"4356_CR19","first-page":"100140","volume":"11","author":"G Fagherazzi","year":"2023","unstructured":"Fagherazzi G (2023) Technologies will not make diabetes disappear: how to integrate the concept of diabetes distress into care. Diab Epidemiol Manag 11:100140","journal-title":"Diab Epidemiol Manag"},{"key":"4356_CR20","unstructured":"Febrianto D, Soelistijo SA, Tjempakasari A (2020) Correlation between serum high-sensitivity C-reactive protein level and severity of albuminuria measured by urine albumin-to-creatinine ratio in type 2 diabetic patients."},{"key":"4356_CR21","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1002\/cpz1.78","volume":"1","author":"BL Furman","year":"2021","unstructured":"Furman BL (2021) Streptozotocin-induced diabetic models in mice and rats. Current Protocols 1:e78","journal-title":"Current Protocols"},{"key":"4356_CR22","doi-asserted-by":"publisher","first-page":"1204905","DOI":"10.3389\/fphar.2023.1204905","volume":"14","author":"J Gauvin","year":"2023","unstructured":"Gauvin J, Fregeau G, Elimam H, Menard L, Huynh D, Le C, Ahsanullah A, Lubell WD, Ong H, Marleau S (2023) A cyclic azapeptide ligand of the scavenger receptor CD36\/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice. Front Pharmacol 14:1204905","journal-title":"Front Pharmacol"},{"key":"4356_CR23","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.3390\/ijms22094824","volume":"22","author":"G Gembillo","year":"2021","unstructured":"Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, Trifir\u00f2 G (2021) Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia. Int J Mol Sci 22:4824","journal-title":"Int J Mol Sci"},{"key":"4356_CR24","first-page":"274","volume":"22","author":"A Ghasemi","year":"2023","unstructured":"Ghasemi A, Jeddi S (2023) Streptozotocin as a tool for induction of rat models of diabetes: a practical guide. EXCLI J 22:274","journal-title":"EXCLI J"},{"key":"4356_CR25","doi-asserted-by":"crossref","unstructured":"Goldstein DL (2022) Renal and extrarenal regulation of body fluid composition. Sturkie\u2019s avian physiology. Elsevier, pp. 411\u2013443","DOI":"10.1016\/B978-0-12-819770-7.00034-7"},{"key":"4356_CR26","doi-asserted-by":"crossref","unstructured":"Guo L, Jiang B, Li D, Xiao X (2021) Nephroprotective effect of adropinin against streptozotocin-induced diabetic nephropathy in rats: inflammatory mechanism and YAP\/TAZ factor. Drug Des Devel Ther 589\u2013600","DOI":"10.2147\/DDDT.S294009"},{"key":"4356_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237\u2013244","journal-title":"Kidney Int"},{"key":"4356_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1442-2042.2010.02644.x","volume":"17","author":"T Hayashi","year":"2010","unstructured":"Hayashi T, De Velasco MA, Saitou Y, Nose K, Nishioka T, Ishii T, Uemura H (2010) Carvedilol protects tubular epithelial cells from ischemia\u2013reperfusion injury by inhibiting oxidative stress. Int J Urol 17:989\u2013995","journal-title":"Int J Urol"},{"key":"4356_CR29","doi-asserted-by":"publisher","first-page":"4314415","DOI":"10.1155\/2022\/4314415","volume":"2022","author":"Y Hu","year":"2022","unstructured":"Hu Y, Wang S-X, Wu F-Y, Wu K-J, Shi R-P, Qin L-H, Lu C-F, Wang S-Q, Wang F-F, Zhou S (2022) Effects and mechanism of ganoderma lucidum polysaccharides in the treatment of diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int 2022:4314415","journal-title":"Biomed Res Int"},{"key":"4356_CR30","doi-asserted-by":"publisher","first-page":"1185317","DOI":"10.3389\/fimmu.2023.1185317","volume":"14","author":"Q Jin","year":"2023","unstructured":"Jin Q, Liu T, Qiao Y, Liu D, Yang L, Mao H, Ma F, Wang Y, Peng L, Zhan Y (2023a) Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front Immunol 14:1185317","journal-title":"Front Immunol"},{"key":"4356_CR31","doi-asserted-by":"publisher","first-page":"1185317","DOI":"10.3389\/fimmu.2023.1185317","volume":"14","author":"Q Jin","year":"2023","unstructured":"Jin Q, Liu T, Qiao Y, Liu D, Yang L, Mao H, Ma F, Wang Y, Peng L, Zhan Y (2023) Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front Immunol 14:1185317","journal-title":"Front Immunol"},{"key":"4356_CR32","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2174\/1567201819666220914113324","volume":"20","author":"R Kadian","year":"2023","unstructured":"Kadian R, Nanda A (2023) A comprehensive insight on recent advancements in self-emulsifying drug delivery systems. Curr Drug Deliv 20:1095\u20131114","journal-title":"Curr Drug Deliv"},{"issue":"12","key":"4356_CR33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10157-024-02537-z","volume":"28","author":"K Kanasaki","year":"2024","unstructured":"Kanasaki K, Ueki K, Nangaku M (2024) Diabetic kidney disease: the kidney disease relevant to individuals with diabetes. Clin Exp Nephrol 28(12):1213\u201320","journal-title":"Clin Exp Nephrol"},{"key":"4356_CR34","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.xphs.2017.01.001","volume":"106","author":"M Khalid","year":"2017","unstructured":"Khalid M, Ahmed TA, Ahmed OA, Hosny KM, Abd-Allah FI (2017) Self-nanoemulsifying lyophilized tablets for flash oral transmucosal delivery of vitamin K: development and clinical evaluation. J Pharm Sci 106:2447\u20132456","journal-title":"J Pharm Sci"},{"key":"4356_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1439-0272.2009.00932.x","volume":"41","author":"A Kheradmand","year":"2009","unstructured":"Kheradmand A, Alirezaei M, Asadian P, Rafiei Alavi E, Joorabi S (2009) Antioxidant enzyme activity and MDA level in the rat testis following chronic administration of ghrelin. Andrologia 41:335\u2013340","journal-title":"Andrologia"},{"key":"4356_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1573399819666230328151108","volume":"20","author":"F Khonsha","year":"2024","unstructured":"Khonsha F, Valilo M, Nejabati H-R, Rahmati-Yamchi M, Mota A (2024) Biomarkers for diabetic nephropathy with a focus on kidney injury molecule-1 (KIM-1). Curr Diabetes Rev 20:67\u201375","journal-title":"Curr Diabetes Rev"},{"key":"4356_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/B978-0-12-815876-0.00019-X","volume-title":"Chronic Renal Disease (Second Edition)","author":"CC Khoury","year":"2020","unstructured":"Khoury CC, Chen S, Ziyadeh FN (2020) Chapter 19 - Pathophysiology of diabetic nephropathy. In: Kimmel PL, Rosenberg ME (eds) Chronic Renal Disease (Second Edition). Academic Press, pp 279\u2013296"},{"key":"4356_CR38","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1016\/S0024-3205(00)00594-4","volume":"66","author":"KV Kumar","year":"2000","unstructured":"Kumar KV, Shifow AA, Naidu M, Ratnakar K (2000) Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci 66:2603\u20132611","journal-title":"Life Sci"},{"key":"4356_CR39","first-page":"838","volume":"9","author":"R Kumar","year":"2020","unstructured":"Kumar R, Saha P, Kumar Y, Sahana S, Dubey A, Prakash O (2020) A review on diabetes mellitus: type1 & type2. World J Pharm Pharm Sci 9:838\u2013850","journal-title":"World J Pharm Pharm Sci"},{"key":"4356_CR40","doi-asserted-by":"publisher","first-page":"113057","DOI":"10.1016\/j.biopha.2022.113057","volume":"150","author":"X-T Li","year":"2022","unstructured":"Li X-T (2022) Beneficial effects of carvedilol modulating potassium channels on the control of glucose. Biomed Pharmacother 150:113057","journal-title":"Biomed Pharmacother"},{"key":"4356_CR41","doi-asserted-by":"publisher","first-page":"9370","DOI":"10.1021\/es051043o","volume":"39","author":"LK Limbach","year":"2005","unstructured":"Limbach LK, Li Y, Grass RN, Brunner TJ, Hintermann MA, Muller M, Gunther D, Stark WJ (2005) Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ Sci Technol 39:9370\u20139376","journal-title":"Environ Sci Technol"},{"key":"4356_CR42","unstructured":"Magliano DJ, Boyko EJ (2022) IDF diabetes atlas."},{"key":"4356_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1590\/S0102-86502010000600006","volume":"25","author":"PJ Medeiros","year":"2010","unstructured":"Medeiros PJ, Villarim Neto A, Lima FP, Azevedo IM, Leao LR, Medeiros AC (2010) Effect of sildenafil in renal ischemia\/reperfusion injury in rats. Acta Cir Bras 25:490\u2013495","journal-title":"Acta Cir Bras"},{"key":"4356_CR44","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/ckj\/sfad120","volume":"16","author":"D Memmos","year":"2023","unstructured":"Memmos D, Sarafidis P, Alexandrou ME, Theodorakopoulou M, Anastasiadis A, Mykoniatis I, Dimitriadis G, Hatzichristou D (2023) The effect of standard percutaneous nephrolithotomy, miniaturized percutaneous nephrolithotomy and retrograde intrarenal surgery on biomarkers of renal injury: a randomized clinical trial. Clin Kidney J 16:2216\u20132225","journal-title":"Clin Kidney J"},{"key":"4356_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00003088-199426050-00002","volume":"26","author":"T Morgan","year":"1994","unstructured":"Morgan T (1994) Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 26:335\u2013346","journal-title":"Clin Pharmacokinet"},{"issue":"1042\u20131061","key":"4356_CR46","first-page":"e1047","volume":"33","author":"Y Mori","year":"2021","unstructured":"Mori Y, Ajay AK, Chang JH, Mou S, Zhao H, Kishi S, Li J, Brooks CR, Xiao S, Woo HM, Sabbisetti VS, Palmer SC, Galichon P, Li L, Henderson JM, Kuchroo VK, Hawkins J, Ichimura T, Bonventre JV (2021) KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab 33(1042\u20131061):e1047","journal-title":"Cell Metab"},{"key":"4356_CR47","doi-asserted-by":"publisher","first-page":"105214","DOI":"10.1155\/2014\/105214","volume":"2014","author":"MA Morsy","year":"2014","unstructured":"Morsy MA, Ibrahim SA, Amin EF, Kamel MY, Abdelwahab SA, Hassan MK (2014) Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int 2014:105214","journal-title":"Biomed Res Int"},{"key":"4356_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s13346-022-01193-8","volume":"13","author":"C Rathore","year":"2023","unstructured":"Rathore C, Hemrajani C, Sharma AK, Gupta PK, Jha NK, Aljabali AAA, Gupta G, Singh SK, Yang JC, Dwivedi RP, Dua K, Chellappan DK, Negi P, Tambuwala MM (2023) Self-nanoemulsifying drug delivery system (SNEDDS) mediated improved oral bioavailability of thymoquinone: optimization, characterization, pharmacokinetic, and hepatotoxicity studies. Drug Deliv Transl Res 13:292\u2013307","journal-title":"Drug Deliv Transl Res"},{"key":"4356_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.trsl.2019.04.003","volume":"209","author":"M Rauchman","year":"2019","unstructured":"Rauchman M, Griggs D (2019) Emerging strategies to disrupt the central TGF-\u03b2 axis in kidney fibrosis. Transl Res 209:90\u2013104","journal-title":"Transl Res"},{"key":"4356_CR50","doi-asserted-by":"publisher","first-page":"154890","DOI":"10.1016\/j.metabol.2021.154890","volume":"124","author":"CA Ricciardi","year":"2021","unstructured":"Ricciardi CA, Gnudi L (2021) Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies. Metabolism 124:154890","journal-title":"Metabolism"},{"key":"4356_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cbi.2010.10.014","volume":"189","author":"MC Rodrigues","year":"2011","unstructured":"Rodrigues MC, Rodrigues J, Martins N, Barbosa F, Curti C, Santos N, Santos ACd (2011) Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact 189:45\u201351","journal-title":"Chem Biol Interact"},{"key":"4356_CR52","doi-asserted-by":"crossref","unstructured":"Sagoo MK, Gnudi L (2020) Diabetic nephropathy: an overview. Diabetic nephropathy: methods and protocols: 3\u20137","DOI":"10.1007\/978-1-4939-9841-8_1"},{"key":"4356_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.freeradbiomed.2017.12.040","volume":"116","author":"MK Sagoo","year":"2018","unstructured":"Sagoo MK, Gnudi L (2018) Diabetic nephropathy: is there a role for oxidative stress? Free Radical Biol Med 116:50\u201363","journal-title":"Free Radical Biol Med"},{"key":"4356_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cbi.2014.09.009","volume":"223","author":"BD Sahu","year":"2014","unstructured":"Sahu BD, Koneru M, Bijargi SR, Kota A, Sistla R (2014) Chromium-induced nephrotoxicity and ameliorative effect of carvedilol in rats: involvement of oxidative stress, apoptosis and inflammation. Chem Biol Interact 223:69\u201379","journal-title":"Chem Biol Interact"},{"key":"4356_CR55","doi-asserted-by":"publisher","first-page":"1497449","DOI":"10.1155\/2021\/1497449","volume":"2021","author":"N Samsu","year":"2021","unstructured":"Samsu N (2021) Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. BioMed Res Int 2021:1497449","journal-title":"BioMed Res Int"},{"key":"4356_CR56","doi-asserted-by":"publisher","first-page":"061914","DOI":"10.1103\/PhysRevE.78.061914","volume":"78","author":"W Shi","year":"2008","unstructured":"Shi W, Wang J, Fan X, Gao H (2008) Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells. Phys Rev E 78:061914","journal-title":"Phys Rev E"},{"key":"4356_CR57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3109\/10717544.2011.604686","volume":"18","author":"B Singh","year":"2011","unstructured":"Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OO (2011) Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. Drug Deliv 18:599\u2013612","journal-title":"Drug Deliv"},{"key":"4356_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.colsurfb.2012.07.017","volume":"101","author":"B Singh","year":"2013","unstructured":"Singh B, Singh R, Bandyopadhyay S, Kapil R, Garg B (2013a) Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. Colloids Surf B 101:465\u2013474","journal-title":"Colloids Surf B"},{"key":"4356_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.colsurfb.2012.07.017","volume":"101","author":"B Singh","year":"2013","unstructured":"Singh B, Singh R, Bandyopadhyay S, Kapil R, Garg B (2013b) Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. Colloids Surf B Biointerfaces 101:465\u2013474","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4356_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13020-022-00700-w","volume":"18","author":"Y Sun","year":"2023","unstructured":"Sun Y, Jin D, Zhang Z, Zhang Y, Zhang Y, Kang X, Jiang L, Tong X, Lian F (2023) Effects of antioxidants on diabetic kidney diseases: mechanistic interpretations and clinical assessment. Chin Med 18:3","journal-title":"Chin Med"},{"key":"4356_CR61","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1038\/s41598-020-59411-7","volume":"10","author":"L Tang","year":"2020","unstructured":"Tang L, Li K, Zhang Y, Li H, Li A, Xu Y, Wei B (2020) Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats. Sci Rep 10:2440","journal-title":"Sci Rep"},{"key":"4356_CR62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1440-1797.2007.00796.x","volume":"12","author":"GH Tesch","year":"2007","unstructured":"Tesch GH, Allen TJ (2007) Rodent models of streptozotocin-induced diabetic nephropathy (Methods in Renal Research). Nephrology 12:261\u2013266","journal-title":"Nephrology"},{"key":"4356_CR63","doi-asserted-by":"publisher","first-page":"111918","DOI":"10.1016\/j.biopha.2021.111918","volume":"141","author":"J Wang","year":"2021","unstructured":"Wang J, Xiang H, Lu Y, Wu T, Ji G (2021) New progress in drugs treatment of diabetic kidney disease. Biomed Pharmacother 141:111918","journal-title":"Biomed Pharmacother"},{"key":"4356_CR64","doi-asserted-by":"publisher","first-page":"8054073","DOI":"10.1155\/2018\/8054073","volume":"2018","author":"Y Wang-Fischer","year":"2018","unstructured":"Wang-Fischer Y, Garyantes T (2018) Improving the reliability and utility of streptozotocin-induced rat diabetic model. J Diabetes Res 2018:8054073","journal-title":"J Diabetes Res"},{"key":"4356_CR65","doi-asserted-by":"publisher","first-page":"7495629","DOI":"10.1155\/2019\/7495629","volume":"2019","author":"Y Xiong","year":"2019","unstructured":"Xiong Y, Zhou L (2019) The signaling of cellular senescence in diabetic nephropathy. Oxid Med Cell Longev 2019:7495629","journal-title":"Oxid Med Cell Longev"},{"key":"4356_CR66","doi-asserted-by":"publisher","first-page":"696542","DOI":"10.3389\/fcell.2021.696542","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Jin D, Kang X, Zhou R, Sun Y, Lian F, Tong X (2021) Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev Biol 9:696542","journal-title":"Front Cell Dev Biol"},{"key":"4356_CR67","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fcell.2020.00187","volume":"8","author":"L Zhao","year":"2020","unstructured":"Zhao L, Zou Y, Liu F (2020) Transforming growth factor-beta1 in diabetic kidney disease. Front Cell Dev Biol 8:187","journal-title":"Front Cell Dev Biol"},{"key":"4356_CR68","first-page":"479","volume":"17","author":"W Zheng","year":"2019","unstructured":"Zheng W, Li D, Gao X, Zhang W, Robinson BO (2019) Carvedilol alleviates diabetic cardiomyopathy in diabetic rats. Exp Ther Med 17:479\u2013487","journal-title":"Exp Ther Med"},{"key":"4356_CR69","doi-asserted-by":"publisher","first-page":"118855","DOI":"10.1016\/j.lfs.2020.118855","volume":"265","author":"M Zhu","year":"2021","unstructured":"Zhu M, Wang H, Chen J, Zhu H (2021) Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2\/STAT3\/SOCS1 pathway in streptozotocin-induced diabetic rats. Life Sci 265:118855","journal-title":"Life Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04356-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:02:00Z","timestamp":1764824520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4356"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04356-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the approval of the Experimental Animals Ethics Committee of the Faculty of Pharmacy, Helwan University, Egypt (Protocol No.: 09A2021), and all procedures were consistent with the ethical protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}